Focal epilepsy
First line
First-line for focal epilepsy in adults and children per NG217 2022 and /AES 2018. Start 250–500 mg twice daily; target 1000–3000 mg daily. Efficacy comparable to other first-line antiepileptics (lamotrigine, oxcarbazepine, ), with a generally more favorable profile — minimal drug interactions, no hepatic enzyme induction, and no weight gain.